Article

Is the FDA violating the right to free speech?

I am grateful that my ophthalmologist friend and I live and practice in countries where we are free to speak our minds.

Take-home message: I am grateful that my ophthalmologist friend and I live and practice in countries where we are free to speak our minds.

 

By Peter J. McDonnell, MD

“I disapprove of what you say, but I will defend to the death your right to say it.”

-Evelyn Beatrice Hall (although often misattributed to Voltaire)

My friend (a very skilled ophthalmologist) lives in a country that has been having some difficulties lately: lack of economic growth, fiscal mismanagement, and governmental corruption. Tomorrow, he plans to attend-along with a million or so of his fellow citizens-a public protest calling for a change, via constitutional means, in the political leadership.

Popular blog: Tips for improving a practice's performance when it just isn't cutting it

This does not worry me too much because he lives in a country where people can peacefully assemble and give speeches denouncing what they perceive to be corrupt or incompetent government officials without fearing that they will be tear gassed, beaten, imprisoned, or worse.

Dr. McDonnell

My own country is famous for its defense of “free speech.” We Americans can spout things from our pie holes that are incredibly ridiculous and inane and get away with it (for proof of this, simply listen to some of the candidates aspiring to the presidency of this fair land).

Debate: Combatting UPP at the source

We are not supposed to yell “Fire!” in a crowded theater, when there is no fire, because of the physical danger that would pose to innocent moviegoers that could be hurt in a stampede to the exits. But along with some other mostly reasonable exceptions designed to protect the safety of others, we can pretty much say what we want.

Next: "Federal judges are saying the FDA has violated the sacred American right to free speech"

 

Freedom of information

So, it is with interest that I read news reports about a dispute within the U.S. government on the issue of free speech. The dispute is between the federal courts and the FDA as to whether employees of pharmaceutical companies may speak the truth to physicians if that truth might lead the doctors to use a medicine for an off-label indication, for which the FDA has not deemed the drug to have been proven safe and effective.

Hot right now: Online vision testing causes stire within eyecare community

The FDA interprets the law as requiring the agency to make certain that drugs are marketed only for conditions for which they are approved (by the FDA) to treat. The agency has therefore criminally prosecuted companies and individual salespersons and other employees of companies and demanded large fines for sharing information with physicians, even if that information is obviously truthful, that includes information about unapproved use of the drug.

Now, federal judges are saying the FDA has violated the sacred American right to free speech. In January 2013, the federal appellate court in Brooklyn, NY, rules that Frederick Cordonia, a drug company employee, could not be denied the ability to provide truthful information.

The FDA did not appeal the decision, but subsequently tried to stop a company called Amarin Pharma from sharing information that its fish oil-derived drug (Vascepa) could reduce serum triglycerides is people with elevated levels (the FDA wants the company to only speak about people with “severely elevated” levels).

Top 10 ophthalmic advancements over past 20 years

In a separate court, U.S. District Judge Paul A. Engelmayer has recently ruled that the First Amendment allows Amarin to engage in “truthful and non-misleading speech” about what this drug can do.

Next: Taking on faith that government, FDA doing best to follow laws

 

I take it on faith that my governmental employees, FDA staff, and federal judges are doing their best to follow the constitution and our laws as they best interpret them. And I am grateful that my ophthalmologist friend and I live and practice in countries where we are free to speak our minds.

P.S. In the interest of full disclosure, the author of this editorial is a co-founder of a start-up pharmaceutical company and a board member of Allergan plc.

 

More from Dr. McDonnell

Should high-volume surgeons have surgical privileges?

Best practices for injection protocols

The economics of 'diabesity'

When a doctor is at the center of political corruption scandal

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.